Extrait

To evaluate the comparative bioavailability between: •Raltegravir/lamivudine (MK-0518B) 300 mg/150 mg Fixed-Dose Combination (FDC) tablets from Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., USA and •ISENTRESS® 400 mg tablets from Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., USA co-administered with EPIVIR® 150 mg tablets from ViiV Healthcare UK Limited, United Kingdom after a single-dose in healthy subjects under fasting conditions.

Critère d'inclusion

• N/A

Liens

• euctr